| Ovarian cancer is one of the most common gynecological tumor. The incidence of the disease is the third which is near to carcinoma of cervix uteri and corpus uteri. But ovarian cancer is the leading cause of all kinds of gynecological cancer deaths. It's survival rate of 5 years is wandering 25% to 30%. Surgery is the major treatment, chemotherapy and radiotherapy are the assisted treatment. But ovarian cancer frequently recurs following primary surgery and combination chemotherapy or radiotherapy. And further more in advance stage and relapse patients are all most resist to standard chemotherapy or radiotherapy. Therefore, it is quite necessary to improve effect and survival rate of ovarian cancer that exploring comprehensive therapy measures comprising biotherapy. The development of biotherapy is in recent years, which is named the fourth treatment of malignant tumors. It has developed rapidly in recent 20 years, especially utilizing recombinant DNA technology to engineer viruses. E1B-55KDa gene-deleted replication-selective adenovirus is one of them. It makes use of the different state of P53 in cells and uses gene engineering method to engineer adenovirus, then makes the adenovirus only selectively-replicate in lacking functional P53 cancer cells. Then the adenovirus replicates rapidly and lyses the cells. The study aimed at comprehensive therapy of ovarian cancer, and suggested the treatment of low-dose chemotherapy combined with E1B-deleted adenoviru(sH101), to observed the inhibition of ovarian cancer cell in vitro and evaluated feasibility of clinical application. Thereby, it can provide theoretic and experimental basis for clinical comprehensive treatment of ovarian cancer.Objective : To explore the effect of E1B gene-deleted adenovirus...
|
PDF Full Text Request